AB Science Delays Key Trials After GCP Inspection, Overhauls Quality Systems
Event summary
- AB Science delays AB8939 Phase 1 trial (AML) to Q1 2027 and masitinib Phase 3 trial (ALS) to Q4 2027 following GCP inspection.
- Company prioritizes overhaul of quality management system by year-end 2026 to ensure data robustness.
- Sickle cell disease program with AP-HP unaffected, set to begin Q1 2027.
- Half-year financial report due by October 9, 2026, outlining new ambitions.
The big picture
AB Science’s delays reflect broader industry challenges in maintaining rigorous clinical trial standards amid heightened regulatory scrutiny. The overhaul of its quality management system underscores the strategic importance of data reliability in securing future partnerships and approvals. The company’s ability to navigate these hurdles will be critical in maintaining momentum in its key therapeutic areas.
What we're watching
- Regulatory Compliance
- Whether AB Science can fully address GCP inspection findings and secure health authority approvals for resumed trials.
- Execution Risk
- The pace at which the company implements its new quality management system and resumes clinical studies.
- Strategic Pivot
- How AB Science’s revised development plan impacts partnering efforts and investor confidence.